Sesen Bio
SESN

From December 31, 2021 to December 31, 2022 Exercises of stock options Issuance of common stock for RSU vesting

From June 30, 2022 to September 30, 2022 Share-based compensation

From June 30, 2021 to September 30, 2021 Exercises of stock options Exercises of common stock warrants Issuance of common stock under ATM Offering, net of issuance costs of $1.2 million

From March 31, 2021 to June 30, 2021 Issuance of common stock under ATM Offering, net of issuance costs of $2.0 million

From December 31, 2020 to March 31, 2021 Exercises of stock options Exercises of common stock warrants Issuance of common stock under ATM Offering, net of issuance costs of $2.2 million

From December 31, 2019 to December 31, 2020 Exercises of stock options Sales of common stock under 2014 ESPP Exercises of common stock warrants Issuance of common stock under ATM Offering, net of issuance costs of $1,174

From June 30, 2020 to September 30, 2020 Sales of common stock under 2014 ESPP Issuance of common stock under ATM Offering, net of issuance costs of $0.3 million

From March 31, 2020 to June 30, 2020 Issuance of common stock under ATM Offering, net of issuance costs of $0.1 million

From December 31, 2019 to March 31, 2020 Sales of common stock under 2014 ESPP Issuance of common stock under ATM Offering, net of issuance costs of $98k

From December 31, 2018 to December 31, 2019 Exercises of stock options Sales of common stock under 2014 ESPP Issuance of common stock and common stock warrants, net of issuance costs of $2,171 Exercises of common stock warrants Issuance of common stock under ATM Offering, net of issuance costs of $212

from June 30, 2019 to September 30, 2019 Sales of common stock under 2014 ESPP

from March 31, 2019 to June 30,2019 Exercise of stock options Exercise of common stock warrants Issuance of common stock and common stock warrants, net of issuance costs

from December 31, 2018 to March 31, 2019 Issuance of common stock pursuant to the 2014 ESPP

from December 31, 2017 to December 31, 2018 Exercise of stock options and vesting of restricted stock awards Issuance of common stock pursuant to the ESPP Exercise of common stock warrants Issuance of common stock and common stock warrants, net of issuance costs of $5.1 million

On May 30, 2018, Sesen Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Canaccord Genuity LLC, as representatives of the several underwriters identified in Schedule A thereto (the “Underwriters”), relating to the offering, issuance and sale (the “Offering”) of 22,222,223 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a public offering price of $1.80 per share less the underwriting discounts and commissions. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 3,333,333 shares of Common Stock at the same price (the “Option Shares,” and together with the Firm Shares, the “Shares”). On May 31, 2018, the Underwriters fully exercised the option for an additional 3,333,333 Option Shares. The closing of the sale of the Shares in the Offering is expected to occur on or about June 4, 2018, subject to customary closing conditions.

from December 31, 2016 to December 31, 2017 Exercise of stock options and vesting of restricted stock awards Issuance of common stock pursuant to the ESPP Issuance of common stock and common stock warrants, net of issuance costs of $1 million Exercise of pre-funded common stock warrants

from December 31, 2015 to December 31, 2016 Exercise of stock options and vesting of restricted stock awards Issuance of common stock pursuant to the ESPP Issuance of common stock in connection with the acquisition of Viventia

from December 31, 2014 to December 31, 2015 Issuance of common stock, net of issuance costs of $819,000 Exercise of stock options and vesting of restricted stock awards

From December 31,2013 to December 31,2014 Initial public offering, net of issuance costs of $7.3 million Issuance of common stock, net of issuance costs of $1.5 million Exercise of stock options and vesting of restricted stock awards Exercise of warrants The Company effected a one-for-6.35 reverse stock split of its issued and outstanding Common Stock on January 21, 2014. The automatic conversion of all outstanding shares of our preferred stock into an aggregate of 8,260,444 shares of our common stock upon the closing of this offering

the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 8,260,444 shares of our common stock upon the closing of this offering

The Company effected a one-for-6.35 reverse stock split of its issued and outstanding Common Stock on January 21, 2014.

From December 31,2012 to December 31,2013 Exercise of stock awards and vesting of restricted stock awards Issuance of series B convertible preferred stock, net of issuance costs of $163 Issuance of series B convertible preferred stock upon the conversion of notes payable Exercise of warrants

from December 31, 2012 to September 30, 2013 Exercise of stock awards and vesting of restricted stock awards